Catalent, Inc. (NYSE:CTLT) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System decreased its position in Catalent, Inc. (NYSE:CTLT) by 4.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 154,304 shares of the company’s stock after selling 6,729 shares during the quarter. New York State Teachers Retirement System owned 0.09% of Catalent worth $8,677,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CTLT. Nisa Investment Advisors LLC raised its stake in Catalent by 1.7% during the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after acquiring an additional 185 shares during the period. Lindbrook Capital LLC raised its position in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the last quarter. Czech National Bank boosted its position in Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after purchasing an additional 228 shares during the period. Finally, BNP Paribas Asset Management Holding S.A. grew its stake in Catalent by 1.9% during the 4th quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock worth $802,000 after buying an additional 328 shares during the last quarter.

Insider Buying and Selling

In related news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Catalent news, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the sale, the insider now directly owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The disclosure for this sale can be found here. Insiders have sold 14,810 shares of company stock worth $858,941 in the last ninety days. 0.31% of the stock is currently owned by corporate insiders.

Catalent Price Performance

Shares of Catalent stock opened at $59.44 on Friday. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $60.20. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The stock has a market cap of $10.76 billion, a PE ratio of -9.74, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16. The company’s 50-day moving average price is $57.98 and its two-hundred day moving average price is $56.85.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Barclays boosted their price target on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Finally, StockNews.com initiated coverage on Catalent in a report on Sunday. They set a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $56.83.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.